FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 223 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer April 23, 2021 Taking Time for the Everyday Things in 2024 December 29, 2023 ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... July 21, 2025 FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... July 31, 2025 Load more HOT NEWS Breast Cancer Patient Is Accused of Having “Body Image Issues” After... FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection Restaurant Opens Early For A 3-Year-Old Girl With Leukemia So She... How to Talk About Advanced Cancer Care Planning: An Expert Discussion
